Detalles de la búsqueda
1.
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma.
Br J Cancer
; 124(4): 744-753, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33311588
2.
Investigating the effect of autoinduction in cynomolgus monkeys of a novel anticancer MDM2 antagonist, idasanutlin, and relevance to humans.
Xenobiotica
; 46(8): 667-76, 2016 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26586447
3.
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.
Lancet Oncol
; 13(11): 1133-40, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23084521
4.
Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity study.
Ther Adv Med Oncol
; 15: 17588359231183680, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37492633
5.
Effect of FCGR2A and FCGR3A variants on CLL outcome.
Blood
; 116(20): 4212-22, 2010 Nov 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-20705761
6.
Oxide Metallurgy Technology in High Strength Steel: A Review.
Materials (Basel)
; 15(4)2022 Feb 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35207891
7.
Effect of Cerium on the Microstructure and Inclusion Evolution of C-Mn Cryogenic Vessel Steels.
Materials (Basel)
; 14(18)2021 Sep 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-34576484
8.
Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b studyâ.
Leuk Res
; 100: 106489, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33302031
9.
Lack of UGT polymorphism association with idasanutlin pharmacokinetics in solid tumor patients.
Cancer Chemother Pharmacol
; 83(1): 209-213, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30511219
10.
A single-center, open-label study investigating the excretion balance, pharmacokinetics, metabolism, and absolute bioavailability of a single oral dose of [14C]-labeled idasanutlin and an intravenous tracer dose of [13C]-labeled idasanutlin in a single cohort of patients with solid tumors.
Cancer Chemother Pharmacol
; 84(1): 93-103, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31062077
11.
Phase 1 summary of plasma concentration-QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML.
Cancer Chemother Pharmacol
; 81(3): 597-607, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29392451
12.
Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 81(3): 529-537, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29368050
13.
Dose-Dependent Effect of Piragliatin, a Glucokinase Activator, on the QT Interval Following Short-Term Multiple Doses in Patients With Type 2 Diabetes Mellitus.
Clin Pharmacol Drug Dev
; 6(3): 258-265, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-27364955
14.
An apparent clinical pharmacokinetic drug-drug interaction between bevacizumab and the anti-placental growth factor monoclonal antibody RO5323441 via a target-trapping mechanism.
Cancer Chemother Pharmacol
; 79(4): 661-671, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28314990
15.
Effects of piragliatin, a glucokinase activator, on fasting and postprandial plasma glucose in patients with type 2 diabetes mellitus.
J Clin Pharmacol
; 56(2): 231-8, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26183686
16.
Exploratory effects of a strong CYP3A inhibitor (ketoconazole), a strong CYP3A inducer (rifampicin), and concomitant ethanol on piragliatin pharmacokinetics and pharmacodynamics in type 2 diabetic patients.
J Clin Pharmacol
; 56(5): 548-54, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-26272330
17.
Lack of Potential Pharmacokinetic and Pharmacodynamic Interactions Between Piragliatin, a Glucokinase Activator, and Simvastatin in Patients With Type 2 Diabetes Mellitus.
J Clin Pharmacol
; 56(6): 675-82, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-26381165
18.
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.
Clin Cancer Res
; 22(4): 868-76, 2016 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26459177
19.
Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors.
J Clin Oncol
; 22(16): 3366-74, 2004 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-15310782
20.
Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 76(3): 587-95, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26210682